Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices

European Journal of Pharmacology
M P JohnsonD E Nichols

Abstract

The primary amines 3,4-methylenedioxyamphetamine (MDA), and 1-(1,3-benzodioxol-5-yl)-2-butanamine (BDB) were measured for efficacy in release of [3H]serotonin (5-HT) from rat hippocampal slices, and release of [3H]dopamine (DA) from rat caudate nucleus slices. The N-methyl derivatives of MDA and BDB, MDMA and MBDB, respectively, and the optical antipodes of these four agents were compared in this paradigm. All of the test compounds demonstrated a similar efficacy of [3H]5-HT release in the micromolar concentration range. No significant stereoselectivity was seen in measurements of 5-HT release. However, striking differences were found between the test compounds when [3H]DA release was studied. N-methylation of racemic MDA resulted in a decreased ability to release DA, while side chain extension from alpha-methyl to alpha-ethyl completely abolished this activity. Stereoselectivity for the S-(+)-isomers of MDA and MDMA was also demonstrated in the DA release studies. Correlation of these biochemical findings with human subjective reports indicates that serotonin release may play a more important role in the mechanism of action than does dopamine release.

References

Dec 1, 1978·Neuropharmacology·G ShearmanH Lal
Oct 1, 1976·The Journal of Nervous and Mental Disease·R YensenA A Kurland
Jan 1, 1985·Clinical Neuropharmacology·L LembergerR L Zerbe
Dec 10, 1985·European Journal of Pharmacology·D R GehlertW Lovenberg
Oct 1, 1986·Journal of Medicinal Chemistry·D E NicholsA T Shulgin
Nov 1, 1986·Journal of Pharmacological Methods·A J HoffmanD E Nichols
Jan 1, 1982·Psychopharmacology·R B Carter, J D Leander

Citations

Mar 1, 1993·Naunyn-Schmiedeberg's Archives of Pharmacology·J L Fitzgerald, J J Reid
Jan 1, 1989·Psychopharmacology·L H Gold, G F Koob
Sep 1, 1995·Psychopharmacology·K E SabolL S Seiden
Apr 15, 2004·Psychopharmacology·M Isabel ColadoA Richard Green
Mar 28, 2007·Psychopharmacology·Clara TouriñoOlga Valverde
Apr 18, 2009·Molecular Neurobiology·João Paulo CapelaFélix Carvalho
Apr 27, 1988·European Journal of Pharmacology·G BattagliaE B De Souza
Oct 26, 1988·European Journal of Pharmacology·C J Schmidt, V L Taylor
Mar 29, 1988·European Journal of Pharmacology·B K Yamamoto, L J Spanos
Aug 2, 1988·European Journal of Pharmacology·B J LoganY B Yee
Sep 13, 1989·European Journal of Pharmacology·R A GazzaraS G Howard
May 31, 1990·European Journal of Pharmacology·C J SchmidtV L Taylor
Nov 27, 1990·European Journal of Pharmacology·C J SchmidtV L Taylor
Nov 27, 1990·European Journal of Pharmacology·J L Fitzgerald, J J Reid
Feb 7, 1991·European Journal of Pharmacology·M J Millan, F C Colpaert
Jul 23, 1991·European Journal of Pharmacology·J F Nash, D E Nichols
Apr 7, 1992·European Journal of Pharmacology·C W Callaway, M A Geyer
Feb 1, 1988·Pharmacology, Biochemistry, and Behavior·G BattagliaE B De Souza
Dec 1, 1988·Pharmacology, Biochemistry, and Behavior·M D Schechter
May 1, 1989·Pharmacology, Biochemistry, and Behavior·M P Johnson, D E Nichols
Aug 1, 1989·Pharmacology, Biochemistry, and Behavior·R T MatthewsG D Frye
Jun 1, 1989·Pharmacology, Biochemistry, and Behavior·M HiramatsuA K Cho
Nov 1, 1989·Pharmacology, Biochemistry, and Behavior·T CrispM D Schechter
Nov 1, 1989·Pharmacology, Biochemistry, and Behavior·D E NicholsM P Johnson

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.